24/7 Market News – (NASDAQ: DBTX) shares are poised to gain as they report top line data from Phase 1 trial.

Shares are at bid at $2.55 and do not trade much for premarket. The stocks highest volume day was in 2021 with only 4 million shares traded.  The stock has drifted down over the past year on light volume.  

[mstock id=”73007″ asset=”dbtx”]

Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

https://www.globenewswire.com/news-release/2022/06/28/2470202/0/en/Decibel-Therapeutics-Reports-Positive-Data-from-Interim-Analysis-of-Ongoing-Phase-1b-Clinical-Trial-of-DB-020-in-Patients-Receiving-Cisplatin-Chemotherapy.html

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.